Specialties

Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease. 

According to current research, linagliptin had a significantly lower risk of hypoglycemia and adverse events in geriatric patients with type 2 diabetes. 

Identifying high-risk patients with unstable HbA1c levels from childhood to adolescence can have significant outcomes. 

Evidence suggests A1C levels higher than 7% increase the risks of cardiovascular events in patients 70 years or older with T2D. 

How do factors such as insulin use and blood glucose control impact the overall risk of developing diabetic complications 5 years after type 2 diagnosis?

During pregnancy, insulin resistance increases and caffeine metabolism decreases, affecting maternal cardiometabolic health.

Is current evidence supportive of metformin as an adjunct therapy for pregnant women with diabetes?

The interaction between systolic blood pressure (SBP) and the effects of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).

SGLT2 inhibitors are not created equal; patient-specific characteristics need to be considered for best efficacy.

Is weight loss always as beneficial as we think?